← IONIS PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $84.7m | $129.6m | $278.8m | $683.3m | $397.7m | $869.2m | $276.5m | $399.3m | $242.1m | $372.3m | |
| Short-term Investments | $580.5m | $893.1m | $1.8b | $1.8b | $1.5b | $1.2b | $1.7b | $1.9b | $2.1b | $2.3b | |
| Inventory, Net | $7.5m | $10.0m | $8.6m | $18.2m | $22.0m | $24.8m | $22.0m | $28.4m | $12.5m | $10.0m | |
| Assets, Current | $797.9m | $1.2b | $2.2b | $2.7b | $2.1b | $2.3b | $2.2b | $2.6b | $2.6b | $3.0b | |
| Property, Plant and Equipment, Net | $92.8m | $121.9m | $132.2m | $153.7m | $181.1m | $178.1m | $74.3m | $71.0m | $94.3m | $123.0m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $12.6m | $13.1m | $18.0m | $181.5m | $171.9m | $161.9m | $238.5m | |
| Other Assets, Noncurrent | — | $10.1m | $12.9m | $27.6m | $50.0m | $59.6m | $75.3m | $105.3m | $127.3m | $171.6m | |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, Current | $36.0m | $66.6m | $48.4m | $66.8m | $90.2m | $88.6m | $140.1m | $147.9m | $108.4m | $106.1m | |
| Assets | $912.5m | $1.3b | $2.7b | $3.2b | $2.4b | $2.6b | $2.5b | $3.0b | $3.0b | $3.5b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $2.0m | $2.0m | $2.6m | $7.2m | $8.1m | $9.1m | $9.5m | |
| Accounts Payable, Current | $21.1m | $24.9m | $28.7m | $16.1m | $17.2m | $11.9m | $17.9m | $26.0m | $43.0m | $28.1m | |
| Operating Lease, Liability, Noncurrent | — | — | — | — | — | — | $178.9m | $170.9m | $161.8m | $262.4m | |
| Deferred Revenue, Current | $51.3m | $106.5m | $160.3m | $118.3m | $108.4m | $97.7m | $90.6m | $151.1m | $79.0m | $73.8m | |
| Deferred Revenue, Noncurrent | $91.2m | $72.7m | $160.3m | $118.3m | $108.4m | $97.7m | $90.6m | $151.1m | $79.0m | $73.8m | |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | $1.2b | $1.2b | $1.2b | $1.3b | |
| Long-term Debt, Current Maturities | — | — | — | — | — | — | $151k | $157k | $165k | $432.1m | |
| Liabilities, Current | $133.8m | $224.7m | $280.3m | $273.0m | $583.2m | $240.6m | $311.6m | $448.1m | $309.3m | $781.6m | |
| Other Liabilities, Noncurrent | — | — | — | — | — | — | $7.1m | — | — | — | |
| Liabilities | $812.9m | $903.3m | $1.5b | $1.5b | $1.5b | $1.8b | $2.0b | $2.6b | $2.4b | $3.0b | |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, Issued | $122k | $125k | $138k | $140k | $140k | $141k | $142k | $144k | $158k | $163k | |
| Retained Earnings (Accumulated Deficit) | ($1.2b) | ($1.2b) | ($967.3m) | ($707.5m) | ($1.2b) | ($1.2b) | ($1.4b) | ($1.8b) | ($2.2b) | ($2.6b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($30.4m) | ($31.8m) | ($32.0m) | ($25.3m) | ($21.1m) | ($32.7m) | ($57.5m) | ($32.6m) | ($30.8m) | ($25.3m) | |
| Additional Paid in Capital, Common Stock | $1.3b | $1.5b | $2.0b | $2.2b | $2.1b | $2.0b | $2.1b | $2.2b | $2.9b | $3.1b | |
| Stockholders' Equity Attributable to Parent | $99.6m | $330.9m | $1.0b | $1.5b | $843.3m | $771.7m | $572.9m | $386.7m | $588.4m | $489.1m | |
| Stockholders' Equity Attributable to Noncontrolling Interest | — | $87.8m | $139.1m | $213.5m | $0 | — | — | — | — | — | |
| Liabilities and Equity | $912.5m | $1.3b | $2.7b | $3.2b | $2.4b | $2.6b | $2.5b | $3.0b | $3.0b | $3.5b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.